SMPDL3B Human shRNA Plasmid Kit (Locus ID 27293)
CAT#: TR309229
SMPDL3B - Human, 4 unique 29mer shRNA constructs in retroviral untagged vector, 5µg of each construct provided
Need custom shRNA service?
Get a free quote
CNY 6,790.00
货期*
2周
规格
Cited in 1 publication. |
Product images
经常一起买 (2)
Specifications
Product Data | |
Product Name | SMPDL3B Human shRNA Plasmid Kit (Locus ID 27293) |
Locus ID | 27293 |
UniProt ID | Q92485 |
Synonyms | ASML3B |
Vector | pRS |
Format | Retroviral plasmids |
Kit Components | SMPDL3B - Human, 4 unique 29mer shRNA constructs in retroviral untagged vector(Gene ID = 27293). 5µg purified plasmid DNA per construct29-mer scrambled shRNA cassette in pRS Vector, TR30012, included for free. |
RefSeq | NM_001009568, NM_001304579, NM_014474, NM_001009568.1, NM_001009568.2, NM_014474.1, NM_014474.2, NM_014474.3, BC014444, BC014444.1, NM_014474.4 |
Summary | Lipid-modulating phosphodiesterase (PubMed:26095358). Active on the surface of macrophages and dendritic cells and strongly influences macrophage lipid composition and membrane fluidity. Acts as a negative regulator of Toll-like receptor signaling (By similarity). Has in vitro phosphodiesterase activity, but the physiological substrate is unknown (PubMed:26095358). Lacks activity with phosphocholine-containing lipids, but can cleave CDP-choline, and can release phosphate from ATP and ADP (in vitro) (By similarity).[UniProtKB/Swiss-Prot Function] |
shRNA Design | These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com. If you need a special design or shRNA sequence, please utilize our custom shRNA service. |
Performance Guaranteed | OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples. For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred). |
Citations (1)
The use of this RNAi has been cited in the following citations: |
---|
Rituximab Targets Podocytes in Recurrent Focal Segmental Glomerulosclerosis
,Alessia Fornoni, Junichiro Sageshima, Changli Wei, Sandra Merscher-Gomez, Robier Aguillon-Prada, Alexandra N. Jauregui, Jing Li,
Science Translational Medicine, Jun 2011; 3: 85ra46
[SMPDL3B]
|
Documents
Product Manuals |
FAQs |
SDS |
其它SMPDL3B产品
Customer
Reviews
Loading...